{
  "ticker": "PAB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977447",
  "id": "02977447",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250806",
  "time": "0950",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml9mhl7g06bn.pdf",
  "summary": "**Capital Raising Announcement (Pro-Rata Non-Renounceable Entitlement Offer):**  \n- **Structure**: Pro-rata non-renounceable entitlement offer (3:4 ratio) + 1 free attaching share for every 4 new shares.  \n- **Total Capital Raised**: Up to **A$1,774,357** (before costs).  \n- **Issue Price**: **A$0.001** per new share.  \n- **Underwriter**: Templar Corporate Pty Ltd (fully underwritten).  \n- **Use of Proceeds**: Technical work for deoxymabs, IP maintenance, business development, working capital.  \n- **Post-Offer Shares Outstanding**: ~4.58 billion shares (assuming full uptake).  \n- **Options Issuance**:  \n  - 1.03 billion unlisted options to underwriter (exercise price A$0.0016, expiring 30 Nov 2029).  \n  - Additional options/shares for lead manager and placement participants.  \n- **Key Conditions**: Shareholder approval required for underwriter fees (paid in shares/options) at upcoming General Meeting (August 2025).  \n\n**Exclusions**: Ineligible shareholders (non-AU/NZ) excluded.  \n\n**Concise Summary**: Dilutive raising at ultra-low price (A$0.001/share), fully underwritten, significant post-offer dilution (~4.58bn shares), with extensive options issuance.",
  "usage": {
    "prompt_tokens": 1487,
    "completion_tokens": 302,
    "total_tokens": 1789,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-06T00:11:43.685549"
}